Unicycive Therap Action
ActionActionPrix
Questions fréquentes
Quelle est la capitalisation boursière de Unicycive Therap ?
Quel est le bénéfice par action (BPA) de Unicycive Therap ?
Quelles sont les évaluations des analystes et le prix cible de l'action Unicycive Therap ?
Quel est l'EBITDA de Unicycive Therap ?
Quel est le flux de trésorerie disponible de Unicycive Therap ?
Quel est le bêta à 5 ans de l'action Unicycive Therap ?
Combien d'employés compte Unicycive Therap, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Unicycive Therap ?
Finances
Capitalisation boursière
45,71 M $USbêta sur 5 ans
2,19BPA (TTM)
-0,284 $USFree Float
88,00 MEBITDA (TTM)
-28,84 M $USCash-flow disponible (TTM)
-21,66 M $USCotation
Notes des analystes
L'objectif de prix est de 5,30 $US et l'action est analysée par 5 analystes.
Acheter
5
Hold
0
Vendre
0
Informations
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.
14
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire